Meeting
2018 ASCO Annual Meeting
Germline variant alleles in rs12422149 of SLCO2B1 and response to abiraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC).
Authors
Andrew W Hahn
University of Utah Hunstman Cancer Institute, Salt Lake City, UT
Andrew W Hahn , David Michael Gill , Peter Hale , Austin Poole , Roberto Nussenzveig , Sara Wilson , James M. Farnham , Robert A Stephenson , Benjamin Louis Maughan , Lisa Cannon-Albright , Neeraj Agarwal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Epidemiology/Outcomes
Citation
J Clin Oncol 36, 2018 (suppl; abstr 5076)
DOI
10.1200/JCO.2018.36.15_suppl.5076
Abstract #
5076
Poster Bd #
303
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Alliance A031902 (CASPAR): A randomized phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).
First Author: Arpit Rao
Poster
2022 ASCO Annual Meeting
Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).
First Author: Arpit Rao
Poster
2018 Genitourinary Cancers Symposium
Germline variant in SLCO2B1 and response to abiraterone acetate plus prednisone (AA) in men with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Andrew W Hahn
Poster
2024 ASCO Genitourinary Cancers Symposium
The efficacy and safety of tinengotinib in patients with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC).
First Author: Guo Hongqian